Objective To analyze the trends in disease burden, major risk factors, and etiological composition of diarrhea in children under 5 in China from 1990 to 2021, and to predict the disease development trends up to 2030. Methods Data on incidence, mortality, and disability-adjusted life years (DALYs) were extracted from the global burden of disease study (GBD). The Joinpoint regression analysis was employed to examine burden trends, calculating annual average percentage change (AAPC). ARIMA modelling was used for long-term trend analysis and to project indicator trends from 2022 to 2030. Results In 2021, the incidence rate of diarrhea among children under 5 in China was 11 904.60 per 100 000, the DALY rate was 108.99 per 100 000, and the mortality rate was 1.0 per 100 000. Compared to 1990, the AAPC values were ?6.8, ?12.1, and ?12.6, respectively. Disease burden declined substantially over three decades, with the highest mortality and DALY rates observed in neonates aged 0-6 days. The leading risk factor shifted from "childhood malnutrition" in 1990 to "unsafe water source" in 2021. Except for Clostridioides difficile, mortality attributed to all other pathogens decreased significantly. Rotavirus remained the dominant pathogen, but caused 98.63% fewer deaths than in 1990. ARIMA projections indicate continued decline through 2030. Conclusion The burden of diarrhea among children under 5 in China is still going down, and this trend is expected to persist in the future. The main risk factors have changed from "child malnutrition" to "unsafe water sources", and even though rotavirus is still the main pathogen, its impact has been well managed. Future efforts should focus on strengthening vaccination, improving environmental sanitation, and promoting targeted prevention and control to meet the sustainable development goals by 2030.
Citation:
ZHAO Yiwen, HUANG Zirui, CHEN Guo, CHENG Yan, YANG Min. Analysis of the disease burden and risk factors of diarrhea in children under 5 in China from 1990 to 2021 and trend prediction for 2030. Chinese Journal of Evidence-Based Medicine, 2026, 26(10): 1147-1152. doi: 10.7507/1672-2531.202510167
Copy
Copyright ? the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
|
| 2. |
|
| 3. |
|
| 4. |
|
| 5. |
|
| 6. |
|
| 7. |
|
| 8. |
|
| 9. |
|
| 10. |
|
| 11. |
|
| 12. |
|
| 13. |
|
| 14. |
|
| 15. |
|
| 16. |
|
| 17. |
|
| 18. |
|
| 19. |
|
| 20. |
|
| 21. |
|
| 22. |
|
| 23. |
|
| 24. |
|
| 25. |
|
| 26. |
|
| 27. |
|
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.